Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 16 ... that confer clinical resistance to marketed CML therapies imatinib (Gleevec®), dasatinib (Sprycel®), and nilotinib (Tasigna®). "We specifically designed ...
2009 NOV 16 ... in the lab with women's breast cancer cells, Corey found that when the leukemia drug dasatinib is combined with the breast cancer drug doxorubicin, the potent mix inhibits breast ...
2009 NOV 2 ... in the lab with women's breast cancer cells, Corey found that when the leukemia drug dasatinib is combined with the breast cancer drug doxorubicin, the potent mix inhibits breast ...
2009 NOV 16 ... do not respond or develop resistance to the drug, leading to suboptimal responses, Dasatinib and nilotinib are approved second-line compounds for patients experiencing imatinib ...
2009 NOV 16 ... Resistance to imatinib has driven the development of second-line therapies, such as dasatinib, a dual BCR-ABL/SFK inhibitor more potent than imatinib at targeting BCR-ABL....
2009 NOV 1 ... of BCR-ABL mutations in 200 blinded cDNA samples prior to and during second-line dasatinib or nilotinib therapy in patients with chronic myeloid leukemia in whom imatinib ...
2009 NOV 23 ... resistance to imatinib and to subsequent second generation tyrosine kinase inhibitors (dasatinib and nilotinib) due to the T315I mutation. With no currently approved effective treatment ...
2009 NOV 24 ... two small molecule inhibitors of the PDGFR tyrosine kinase (i.e., imatinib and dasatinib) exerted negative effects on fSMC and mSMC growth in ex vivo cultures, albeit at ...
2009 NOV 16 ... maximum tolerated dose, dose-limiting toxicity (DLT), and recommended phase 11 dose of dasatinib in metastatic solid tumors refractory to standard therapies or for which no effective ...
2009 NOV 16 ... the need to reach the cell surface. Inhibition of constitutive Kit TK activity with dasatinib induced a complex, mature N-glycosylation pattern identical to unstimulated wild-type ...
2009 OCT 19 ... cyclophosphamide, vincristine, adriamycin, dexamethasone) plus imatinib/dasatinib or idarubicin plus cytarabine (Ara-C); 2 did not respond, 1 had CCyR, and 1 ...
2009 NOV 2 ... remissions and prolonged survival. With the availability of imatinib, nilotinib and dasatinib, physicians must weigh the efficacy and safety profile of each agent when choosing the ...
2009 NOV 9 ... States report. "of the second-generation tyrosine kinase inhibitors (TKI) dasatinib and nilotinib has provided effective therapeutic options for many patients with ...
2009 NOV 16 ... Src family kinases (SFK). Treatment of cetuximab-resistant cells with the SFK inhibitor, dasatinib, resulted in loss of nuclear EGFR, increased membrane expression of the EGFR and ...
2009 NOV 9 ... of adult ALL. To date, the second generation tyrosine kinase inhibitors Sprycel (dasatinib; Bristol-Myers Squibb) and Tasigna (nilotinib; Novartis) have limited use in the ...
2009 OCT 19 ... signaling pathway, Wnt/b-catenin, that could be targeted by two drugs, vorinostat and dasatinib, both of which are under study in clinical trials. "This is an exploration ...
Subject: The Translational Genomics Research Institute
